FDA Commissioner Scott Gottlieb, M.D. To Address Clinical Laboratory Community at ACLA 2018 Annual Meeting

January 29, 2018 Categories: ACLA News, All News, Featured News, ACLA Press Releases

(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) announced today that Food and Drug Administration (FDA) Commissioner Scott Gottlieb, M.D. will deliver remarks at the association’s annual meeting on March 6 in Washington, D.C. ACLA’s annual conference is the premier meeting for the clinical lab community that brings together national leaders in the diagnostic sector, payors, patients, congressional lawmakers and administration officials for presentations and discussions on federal legislative and regulatory policy.

“We are honored to have Dr. Gottlieb participate in our annual meeting. Dr. Gottlieb brings extensive experience from his public sector positions formerly at FDA and the Centers for Medicare and Medicaid Services (CMS) and his clinical perspective as a practicing physician and clinical assistant professor at New York University School of Medicine,” said Julie Khani, president of ACLA. “The clinical laboratory community is looking forward to hearing from Commissioner Gottlieb on agency initiatives.”

Dr. Gottlieb was sworn in as the 23rd Commissioner of the FDA last year under the Trump Administration. Previously, he was appointed by the U.S. Senate to serve on the Federal Health Information Technology Policy Committee and was a Resident Fellow at the American Enterprise Institute.

For more information and to register to attend, visit the ACLA annual meeting website, click here.

ACLA is a not-for-profit association representing the nation’s leading clinical and anatomic pathology laboratories, including national, regional, specialty, ESRD, hospital and nursing home laboratories. The clinical laboratory industry employs nearly 277,000 people directly and generates over 115,000 additional jobs in supplier industries. Clinical laboratories are at the forefront of personalized medicine, driving diagnostic innovation and contributing more than $100 billion to the nation’s economy.

# # #

Print page / Save as PDF